HUMAN CELL CO
Naperville, IL · Biotech · Private
Manufacturing process and reagents (antibodies, cytokines) for isolating, expanding, and differentiating autologous tumor-infiltrating lymphocyte (TIL) cells for adoptive cell therapy
- Grants
- $4.1M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201720182019202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Optimizing NGF for Topical Treatment of Glaucoma | $299,805 | |
| Federal grant | Department of Health and Human Services · Phase I · Recombinant Prothrombin Therapy for Hemorrhage | $299,575 | |
| Federal grant | Department of Health and Human Services · Phase I · tPA and NGF therapy for stroke | $359,500 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimization of TIL Cell Manufacturing for Cancer Treatment | $400,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimizing NGF for Topical Treatment of Glaucoma | $981,060 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimizing NGF for Topical Treatment of Glaucoma | $991,520 | |
| Federal grant | Department of Health and Human Services · Phase I · Topical NGF Therapy and oral nicotinamide supplementation for Glaucoma | $360,897 | |
| Federal grant | Department of Health and Human Services · Phase I · Topical treatment of an optimized NGF for Dry Eye | $365,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1683 | Canal Biosciences, Inc. | — | $2.3M |
| 1684 | RENOVATE BIOSCIENCES, INC. | — | — |
| 1685 | CORE BIOTHERAPEUTICS INC | — | — |
| 1686 | HUMAN CELL CO | — | — |
| 1687 | SYMBIOTIX BIOTHERAPIES, INC. | — | — |
| 1688 | AscentX Medical, Inc. | — | $3.3M |
| 1689 | Revolve Biotechnologies, Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Method Of Preparing And Expanding A Population Of Immune Cells For Cancer Therapy, Potency Assay For Tumor Recognition, Biological Vaccine Preparation And Epitope Target For Antibodiesapplication
- Ngf Variants, Production, Compositions, And Therapeutic Usesapplication
- Ngf Variants, Production, Compositions, And Therapeutic Usesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.